50 icon

Recommend SHINGRIX to your patients

SHINGRIX is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older.1

SHINGRIX pack shot

What is SHINGRIX?

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older.1

Contraindications:

Patients with a known hypersensitivity to the active substance or to any component of the vaccine.

See Product Monograph

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

View reconstitution instructions for SHINGRIX

You and your office staff can learn how to administer SHINGRIX step by step.

Important product information

Product Monograph

Important safety information

Resources for you and your patients

Important safety information

Indications and clinical use:

  • Indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older

Contraindications:

  • Patients with a known hypersensitivity to the active substance or to any component of the vaccine

Most serious warnings and precautions:

  • Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously

Other relevant warnings and precautions:

  • A protective immune response may not be elicited in all vaccinees
  • Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
  • Postpone in those with acute severe febrile illness
  • Use with caution in those with thrombocytopenia or any coagulation disorder
  • Syncope following or before any vaccination as a psychogenic response
  • Fever and shivering were more frequent when the 23-valent pneumococcal polysaccharide (PPV23) vaccine was co-administered with SHINGRIX
  • Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
  • Limited data in immunocompromised adults 50 years of age or older

Adverse events:

  • Solicited local and general adverse reactions that occurred in clinical trials within 7 days of vaccination in subjects aged 50–69 and ≥70 years respectively were: pain (85.6%, 69.2%), redness (38.5%, 37.7%), swelling at the injection site (28.5%, 23.0%), myalgia (53.0%, 35.1%), fatigue (51.3%, 36.6%), headache (45.2%, 29.0%), shivering (33.1%, 19.5%), fever (25.9%, 14.3%), gastrointestinal symptoms (20.5%, 13.5%)
  • Unsolicited adverse reactions that occurred in clinical trials within 30 days of vaccination in ≥1% of subjects and ≥2-fold higher than placebo recipients included chills (3.5%), injection site pruritus (2.2%), malaise (1.7%)
  • Post-market adverse reactions are: hypersensitivity reactions (rare), including rash, urticaria, angioedema

For more information:

Please consult the product monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions, contraindications and drug interactions which have not been discussed in this piece. To request a product monograph, or to report an adverse event please call 1-800-387-7374.

References

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., June 3, 2020.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
  3. Reproduction of information from the PIQ, 7th ed. Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/.
    The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.
  4. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK Group of Companies or its licensor.

PM-CA-SGX-WCNT-210001 | November 2021